Influenza Vaccine

Company awarded NIH grant for flu-vaccine development

Published in Immunotherapy Weekly, August 31st, 2005

CureLab, Inc., a biotech company with offices in Massachusetts and California, announced that it has been awarded a grant from the U.S. National Institutes of Health (NIH) to continue its development work towards a vaccine against the influenza (flu) virus.

CureLab has developed patent-pending, proprietary technology that it believes will enable it to develop a vaccine that would be effective against all strains of the flu virus, both known and unknown. This award from the NIH is the first phase of a 2-phase grant under the small business innovation research biodefense program. CureLab expects that the total amount of this award will be $7 million.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2005-08-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry